Last reviewed · How we verify

PMZ-1620 along with standard treatment

Pharmazz, Inc. · Phase 2 active Small molecule

PMZ-1620 along with standard treatment is a Small molecule drug developed by Pharmazz, Inc.. It is currently in Phase 2 development. Also known as: Sovateltide (IRL-1620) along with standard treatment.

At a glance

Generic namePMZ-1620 along with standard treatment
Also known asSovateltide (IRL-1620) along with standard treatment
SponsorPharmazz, Inc.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about PMZ-1620 along with standard treatment

What is PMZ-1620 along with standard treatment?

PMZ-1620 along with standard treatment is a Small molecule drug developed by Pharmazz, Inc..

Who makes PMZ-1620 along with standard treatment?

PMZ-1620 along with standard treatment is developed by Pharmazz, Inc. (see full Pharmazz, Inc. pipeline at /company/pharmazz-inc).

Is PMZ-1620 along with standard treatment also known as anything else?

PMZ-1620 along with standard treatment is also known as Sovateltide (IRL-1620) along with standard treatment.

What development phase is PMZ-1620 along with standard treatment in?

PMZ-1620 along with standard treatment is in Phase 2.

Related